Ar hyn o bryd, yn aml bydd cryn amser yn mynd heibio rhwng lansio meddyginiaeth newydd a'r broses o'i harfarnu gan Sefydliad Cenedlaethol dros Iechyd a Rhagoriaeth Glinigol (NICE) ar ran y GIG yng Nghymru a Lloegr. Dim ond pan na ddisgwylir penderfyniad gan NICE am o leiaf 12 mis y bydd Grŵp Strategaeth Feddyginiaethau Cymru Gyfan (AWMSG) yn arfarnu’r meddyginiaethau newydd. Oherwydd bod amserlenni NICE ar gyfer arfarnu meddyginiaethau yn gallu llithro, gall byrddau iechyd fod heb gyngor awdurdodol am feddyginiaeth neu driniaeth penodol am gyfnod. Er mwyn sicrhau bod sylfaen o dystiolaeth briodol ar gael yn sail i benderfyniadau ynghylch cael mynediad at driniaeth, bydd AWMSG bellach yn arfarnu meddyginiaethau dros dro, cyn cael canllawiau gan NICE.
At the moment, there is often a significant time lag between the launch of a new medicine and the appraisal undertaken by the National Institute for Health and Care Excellence (NICE) on behalf of the NHS in Wales and England. The All Wales Medicines Strategy Group (AWMSG) only appraises those new medicines where a decision from NICE is not expected for at least 12 months. As NICE timescales for appraisals can slip, health boards can be without authoritative advice about a particular medicine or treatment for a period of time. To ensure an appropriate evidence base is available to underpin decisions about access to treatments, AWMSG will now undertake interim appraisals ahead of NICE guidance.